EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Economic analysis of adjuvanted trivalent influenza vaccine for older adults in the Korean National Immunization Program

Eunha Shim, Byung Wook Eun, Won Suk Choi

Frontiers in Public Health · 2026

DOI: 10.3389/fpubh.2026.1833971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, 2026. Verfasst von Eunha Shim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics, Soongsil University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Immunization Programs, Adjuvants, Vaccine. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Seasonal influenza causes substantial morbidity and mortality among older adults in South Korea despite high vaccination coverage. The MF59-adjuvanted trivalent influenza vaccine (aTIV) has shown superior immunogenicity in older populations, but its economic value within the Korean National Immunization Program (NIP) has not been evaluated using a dynamic transmission model that captures indirect protection. This study evaluated the budget impact of introducing aTIV into the Korean NIP for adults aged ≥65 years.

Methods

We developed an age-structured dynamic compartmental model to simulate seasonal influenza transmission in South Korea, allowing estimation of both direct and indirect protection effects. From the healthcare payer perspective and over a single influenza season, we performed a budget impact analysis complemented by a cost–benefit comparison of avoided medical costs against incremental vaccination expenditures. Two aTIV strategies were compared against standard quadrivalent influenza vaccine (QIV) within the NIP framework: Strategy I (aTIV for adults aged ≥75 years) and Strategy II (aTIV for all adults aged ≥65 years). Deterministic one-way sensitivity analyses examined relative vaccine effectiveness (rVE) of aTIV versus QIV across 5–30% and seasonal attack rate across ±20% of the 8.0% baseline, and a break-even analysis identified the rVE threshold at which incremental costs equal avoided treatment costs. A probabilistic sensitivity analysis was also conducted to quantify joint parameter uncertainty.

Results

At baseline (rVE 25%, attack rate 8.0%), Strategy I required $24.6 million in additional vaccine investment, with 52% offset by treatment savings, yielding a net budget impact of $11.7 million (+0.9% of total influenza-related healthcare expenditure). Strategy II required $54.4 million in additional costs with 57% offset ($31.2 million in savings), resulting in a net impact of $23.2 million (+1.8%). Strategy II prevented 535 deaths and over 15,000 hospitalizations—2.2-fold greater than Strategy I. The incremental cost of aTIV decreased with increasing transmission intensity, approaching cost neutrality during severe epidemic seasons. The break-even rVE at which aTIV becomes cost-saving was 44%, above central meta-analytic estimates (10–25%) but potentially attainable in severe seasons or specific subpopulations.

Conclusion

Introduction of aTIV into the Korean NIP is budget-feasible with substantial health benefits, requiring only a 0.9–1.8% increase in total influenza-related healthcare expenditure. At current rVE estimates (≤30%), aTIV does not achieve cost savings, but the additional fiscal burden remains modest. Strategy II offers superior health outcome value and is preferred when budget permits, while Strategy I provides a fiscally conservative entry point. The value proposition of aTIV is most favorable during severe influenza seasons.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanImmunization ProgramsAdjuvants, VaccineRepublic of KoreaHumansCost-Benefit AnalysisAgedPolysorbatesAdjuvants, ImmunologicSeasonsSqualeneFemaleMale

Stichwörter der Autor:innen

MF59-adjuvanted vaccineNational Immunization ProgramSouth Koreadynamic transmission modeleconomic analysisinfluenza vaccinationolder population

Substanzen

Influenza VaccinesPolysorbatesAdjuvants, ImmunologicSqualeneAdjuvants, Vaccine

Autor:innen und Institutionen

  • Department of Mathematics, Soongsil University, Seoul, Republic of Korea.
  • Department of Pediatrics, Nowon Eulji University Hospital, Seoul, Republic of Korea.
  • Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea.

Zitieren

APA

Shim, E., Eun, B. W., & Choi, W. S. (2026). Economic analysis of adjuvanted trivalent influenza vaccine for older adults in the Korean National Immunization Program. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2026.1833971

Vancouver

Shim E, Eun BW, Choi WS. Economic analysis of adjuvanted trivalent influenza vaccine for older adults in the Korean National Immunization Program. Frontiers in Public Health. 2026. doi:10.3389/fpubh.2026.1833971

BibTeX
@article{Shim2026,
  author = {Shim, Eunha and Eun, Byung Wook and Choi, Won Suk},
  title = {Economic analysis of adjuvanted trivalent influenza vaccine for older adults in the Korean National Immunization Program},
  journal = {Frontiers in Public Health},
  year = {2026},
  doi = {10.3389/fpubh.2026.1833971}
}
Kostenlos starten →